Norantipyrine glucuronide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 463414

CAS#: 67566-02-3

Description: Norantipyrine glucuronide is a well-recognized lipophilic free radical scavenger for diseases including neurodegenerative disease, cardiovascular disease, and cancer. However, its oral use is restricted due to poor oral bioavailability (BA).

Chemical Structure

img
Norantipyrine glucuronide
CAS# 67566-02-3
Instruction

Theoretical Analysis

MedKoo Cat#: 463414
Name: Norantipyrine glucuronide
CAS#: 67566-02-3
Chemical Formula: C16H18N2O7
Exact Mass: 350.11
Molecular Weight: 350.327
Elemental Analysis: C, 54.86; H, 5.18; N, 8.00; O, 31.97

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Norantipyrine glucuronide; Edaravone glucuronide; MCI 186 glucuronide; MCI186 glucuronide; MCI-186 glucuronide;

IUPAC/Chemical Name: (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-((3-methyl-1-phenyl-1H-pyrazol-5-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

InChi Key: KZSVPEVBRMCCMG-JHZZJYKESA-N

InChi Code: InChI=1S/C16H18N2O7/c1-8-7-10(18(17-8)9-5-3-2-4-6-9)24-16-13(21)11(19)12(20)14(25-16)15(22)23/h2-7,11-14,16,19-21H,1H3,(H,22,23)/t11-,12-,13+,14-,16+/m0/s1

SMILES Code: Cc1nn(c2ccccc2)c(O[C@@H]3O[C@H](C(O)=O)[C@H]([C@@H]([C@H]3O)O)O)c1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 350.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Robertz-Vaupel GM, Lindecken KD, Edeki T, Funke C, Belwon S, Dengler HJ. Disposition of antipyrine in patients with extensive metastatic liver disease. Eur J Clin Pharmacol. 1992;42(5):465-9. doi: 10.1007/BF00314851. PMID: 1606991.

2: Mizuno N, Takahashi T, Iwase Y, Kusuhara H, Niwa T, Sugiyama Y. Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos. 2007 Aug;35(8):1429-34. doi: 10.1124/dmd.106.013912. Epub 2007 May 14. PMID: 17502342.

3: Mizuno N, Takahashi T, Kusuhara H, Schuetz JD, Niwa T, Sugiyama Y. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one). Drug Metab Dispos. 2007 Nov;35(11):2045-52. doi: 10.1124/dmd.107.016352. Epub 2007 Aug 6. PMID: 17682070.

4: Ma L, Sun J, Peng Y, Zhang R, Shao F, Hu X, Zhu J, Wang X, Cheng X, Zhu Y, Wan P, Feng D, Wu H, Wang G. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform. Drug Metab Dispos. 2012 Apr;40(4):734-41. doi: 10.1124/dmd.111.043356. Epub 2012 Jan 11. PMID: 22238289.

5: Parikh A, Kathawala K, Tan CC, Garg S, Zhou XF. Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation. Drug Deliv. 2017 Nov;24(1):962-978. doi: 10.1080/10717544.2017.1337825. PMID: 28633547.